KRas G12D Inhibitor Compounds for Safer Cancer Treatment
Solution Overview
Problem
Current KRas inhibitors have not demonstrated sufficient safety and efficacy for treating KRas G12D-mediated cancer, despite decades of research efforts.
Innovation Solution
Development of compounds represented by Formula (I) that inhibit KRas G12D activity, which are used in pharmaceutical compositions for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing KRas inhibitors are used, then KRas activity is inhibited, but safety and efficacy are insufficient for regulatory approval
Solution Approach 1:
The patent modifies the chemical structure of KRas inhibitors by changing parameters such as introducing specific functional groups (carboxylic acid, ester, amide), adjusting molecular weight, and optimizing binding affinity to achieve sufficient safety and efficacy for regulatory approval
Solution Approach 2:
The invention creates composite inhibitor molecules combining multiple functional moieties (e.g., KRas binding domain plus effector disruption domain) to simultaneously achieve potent KRas inhibition and improved safety profile
2Productivity
If KRas G12D inhibitors are developed, then cancer treatment efficacy is improved, but manufacturing complexity increases
Solution Approach 1:
The patent divides the inhibitor development into modular components: core KRas binding structure, effector disruption moieties, and pharmacokinetic optimization segments, allowing independent optimization of each component while simplifying overall manufacturing
Solution Approach 2:
The invention optimizes manufacturing parameters such as selecting appropriate synthetic routes, controlling purification steps, and establishing scalable production processes to reduce manufacturing complexity while maintaining high treatment efficacy
Data Source
AI summary
The present invention relates to methods of treating cancer with compounds that inhibit KRas G12D. In particular, the present invention relates to methods of treating non-small cell lung cancer, colorectal cancer, and pancreatic cancer by administering a compound of the following formula:or a pharmaceutically acceptable salt thereof.